Introduction
As the cure rate of childhood acute lymphoblastic leukemia (ALL) approaches 80%, 1 international collaboration is required to facilitate further treatment advances. During the 27th Annual Meeting of the International Society of Pediatric Oncology (SIOP) in 1995, representatives of several study groups and institutions agreed to first focus the efforts on highrisk genetic subgroups. 2 This initiative was quickly joined by virtually all major study groups and institutions in Europe and the United States. The first collaboration resulted in a consensus on the management of patients with Philadelphia chromosome-positive (Ph + ) ALL. 3 To facilitate these collaborations, two workshops were held, one at the St Jude Children's Research Hospital (SJCRH) in 1997 and the other in Ponte di Legno, Italy in 1999. The meeting report of the first workshop has been published in this journal. 4 During the second workshop, the participants agreed to report updated long-term results of clinical trials conducted in the 1980s and 1990s, using uniform criteria and format. The intent was to identify effective treatment for certain well-defined subsets of patients. This unprecedented effort resulted in 12 informative articles published together in the December 2000 issue of Leukemia, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] providing valuable clues to advance the cure rate in future trials.
The third international Childhood ALL Workshop organized by C-H Pui, S Sallan, MV Relling, and WE Evans was held on 30 November and 1 December 2000 in Sausalito, California, and attended by representatives from 12 study groups or institutions (see appendix). After the participants were welcomed by the organizers, G Masera provided the historical perspective of the workshop and acknowledged the importance and spirit of the international collaboration.
Philadelphia chromosome-positive ALL
In a multicenter study, childhood Ph + ALL was confirmed to be a heterogeneous disease with respect to treatment outcome. Patients who are younger than 10 years and have a low presenting leukocyte count (Ͻ50 × 10 9 /l) have the most favorable outcome, and those with a leukocyte count /l and age above 10 years) have an intermediate prognosis. Hematopoietic stem cell transplantation from an HLA-matched related donor remains the preferred treatment for all three subgroups of patients.
J Harbott (together with N Heerema) reviewed the karyotypes of 255 evaluable cases from this international study. They found secondary chromosomal aberrations in 157 (62%) of the cases, resulting in unbalanced karyotype in 147 (94%). 17 While all chromosomes were involved in these aberrations, chromosomes 7, 8, 9, 14 and 22 were most frequently affected. The most frequent aberrations, in descending order, were 9p− (n = 55), +Ph (n = 33), monosomy 7 (n = 18), 7p− (n = 12) and hyperdiploidy Ͼ50 (n = 17). Preliminary analysis suggested that 9p−, monosomy 7 and 7p− were associated with dismal prognosis and +Ph, and hyperdiploidy Ͼ50 with better outcome. However, M Valsecchi could not establish the independent prognostic significance of these secondary chromosomal changes in a Cox regression model. M Schrappe suggested further evaluation of the relapsed cases because the additional chromosomal changes at relapse could provide clues to disease progression and drug resistance.
One potentially promising agent for Ph + ALL is STI-571, an ABL tyrosine kinase inhibitor which had been shown to have cytoreductive effects in this disease. 18 It could also have additive or synergistic effects when used in combination with other antileukemic agents, at least in the setting of Ph + chronic myeloid leukemia.
19,20 P Gaynon provided the background and rationale for using this agent, and presented a proposed clinical trial of the Children's Oncology Group (COG), in which Ph + cases will be randomized to receive STI-571 or not, during the intensification and consolidation phases. MV Relling cautioned the group to use the agent judiciously, especially in combination therapy because of drug interactions. This agent has been associated with liver toxicities. 21, 22 One patient who had been taking acetaminophen chronically developed fatal liver failure after the treatment. 21 R Pieters mentioned that there is an ongoing adult pilot study using the combination of STI-571 and cytarabine. A Biondi suggested a window therapy approach to assess the efficacy of the ST1-571 by measuring the levels of minimal residual disease before and after treatment. Finally, there was debate whether the STI-571 study should be conducted on all Ph + cases or only on the high-risk subgroup. S Sallan concluded the discussion by suggesting that after an initial successful study, all groups and institutions be invited to participate in a collaborative randomized trial.
Leukemia

Leukemia with 11q23 rearrangement
ALL with 11q23 rearrangements represent a heterogenous group of disease. While 11q23 translocations generally involve the MLL gene, the deletions or inversions affecting the chromosomal region often lack MLL gene rearrangements. 23 Among cases with MLL rearrangements, most are associated with a poor outcome; however, some have an excellent prognosis, for example, T cell ALL with the t(11;19)(q23;p13.3) and MLL-ENL fusion. 24 There is also heterogeneity among specific genetic subtypes. Among B-lineage ALL cases with the t(4;11)(q21;q23) or t(11;19)(q23;p13.3), infants less than 12 months of age have a poor outcome, whereas those 1 to 9 years old have a relatively favorable prognosis. [24] [25] [26] A limited study suggested that prednisone response can further discriminate two prognostic groups among infants with the t(4;11). 27 However, neither bone marrow nor peripheral blood response after 8 days of remission induction therapy with prednisone, vincristine, daunorubicin and asparaginase, was predictive of event-free survival among 51 infants treated on a recent Medical Research Council (MRC) infant ALL protocol. 28 To more clearly define prognostically important subgroups and to assess the effect of different post-remission therapies on clinical outcome, 497 children with 11q23 rearrangements treated by 11 cooperative groups or large institutions in Europe and the United States were analyzed. C-H Pui, J Boyett and P Harrison presented the preliminary results, which confirmed the previous observation of age differences in outcome. It appeared that any 11q23 translocation conferred a poor prognosis in infants and that presenting leukocyte count had no independent prognostic significance in cases with 11q23 translocations. Ongoing analyses will determine if early treatment response has prognostic impact and if allogeneic transplantation improves treatment outcome.
JM Chessells summarized the experience with infant leukemias in the United Kingdom. Despite recent improvement in treatment outcome for infants with ALL treated on the MRC infant ALL protocol, they still fared significantly worse than infants with acute myeloid leukemia (AML) treated in the MRC AML trials. Rearrangements of 11q23 were found in two-thirds of infant ALL cases and in one-third of infants with AML. The t(9;11) and t (11;19) were the most common 11q23 translocations found in the AML cases. The 20 infant AML cases with 11q23 rearrangements had an event-free survival of approximately 60%, an excellent result reflecting the overall efficacy of the MRC trials. 29 O Haas introduced a concept of an automated interphase FISH screening system that include probes for the enumeration of all chromosomes and for the detection of deletions or duplications of particular chromosomal regions, as well as specific gene fusions. Such a system will consist of combinations of up to 48 dual color-labeled probes on different sections of a single slide, according to a method patented by Cytocell (Oxford, UK). The hybridization patterns of different sections are then examined automatically with an image analysis system and dedicated software developed by Meta Systems (Altlussheim, Germany). This potentially robust and efficient system can be used to screen for particular fusion partners of genes that are involved in a variety of different translocations, such as those affecting the MLL gene. At present, more than 40 different 11q23 translocations are known cytogenetically, 23 of which have been cloned. This novel FISH assay should allow rapid delineation of specific MLL translocations, even in interphase. To this end, a dualcolor 3-Ј and 5-Ј MLL probe set that splits because of translocation has been developed. 30 Eventually, this probe set can be used to hybridize with probes that contain the individual partner genes, for automatic detection of specific 11q23 translocations.
ALL with near-triploidy and near-tetraploidy
In an early study, near-triploid and near-tetraploid ALL cases were found to be distinct entities, different from other cases with hyperdiploidy Ͼ50 chromosomes. 31 Near-tetraploid cases were more likely to have a T-cell immunophenotype (47%) and were older at diagnosis (median age, 8.6 years) than cases in other ploidy groups, and have characteristic leukemic cell morphology (clumped chromatin with grooved nuclei). Because of the small number of cases studied, the prognostic significance of the two ploidies is uncertain.
J Pullen presented the Pediatric Oncology Group (POG) data on near-tetraploidy. Among over 6000 B-lineage cases treated between 1986 and 1999, near-triploidy as defined by DNA index of 1.5 to 1.75 or chromosome number of 68 to 80, was found in 0.28% of cases, and near-tetraploidy as defined by DNA index у1.75 or chromosome number у80 in 0.56%. Near-tetraploidy occurred with a higher frequency in T cell ALL (1.3%). There was no significant difference in treatment outcome between near-triploid, near-tetraploid or hyperdiploid (Ͼ50) cases; however, the statistical power was relatively low because of the small number of patients. Notably, near-tetraploid cases had a high incidence of TEL-AML1 fusion (63%), a finding which may account in part for their relatively favorable prognosis. 32 Participants agreed to further study the clinical significance of these ploidy groups by pooling data. O Haas suggested that instead of arbitrary numbers, the ploidy groups should be defined by histogram distribution and, better yet, by centromere number. To this end, a panel of cytogeneticists will be asked to define the ploidy groups.
Other genetic subgroups
Several genetic subgroups that warrant additional studies were briefly discussed. Hypoploidy Ͻ46 and near-haploidy generally conferred a poor prognosis. 33, 34 However, there also appeared to be clinical heterogeneity in these ploidy groups. J Nachman will coordinate the data collection and analyses for this study. E Vilmer summarized the data on monosomy 7 by the European Organization for Research and Treatment for Cancer and the Children's Cancer Group. The cases are more likely to have a higher frequency of T cell immunophenotype, age over 10 years, the presence of Philadelphia chromosome, CNS leukemia, and poor event-free survival. However, these observations were based on a very small number of cases.
B Camitta described the limited data on the t(17;19)(q21-22;p13) with E2A-HLF fusion. These cases are generally associated with disseminated intravascular coagulation and lytic bone lesions. It was speculated that HLF may be involved in regulating factor IX expression in hepatocytes. All seven cases reported with the E2A-HLF fusion have died as a direct consequence of their leukemia. 35 Recently, S Hunger has identified 16 cases treated in the POG studies. Of the six recent cases, at least three of them remained in long-term continuous complete remission (6.5, 7 and 9.5 years, respectively). Additional studies are needed to determine if contemporary treatment 709 regimens have altered the prognostic significance of this genetic subtype.
Lessons from the long-term follow-up reports
M Schrappe emphasized the importance of international collaboration, and commented on several observations made from the series of 12 long-term follow-up reports published by European and the United States study groups and institutions in the Journal. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] It was noted that even though no new antileukemic agents were introduced in the study period, a steady improvement in event-free survival was noted for all groups and institutions. This success was mainly due to optimization of the use of existing agents. Despite best efforts, comparison of outcome across the studies was still limited by different eligibility criteria, age and ethnic profile, as well as subgroup analyses and incomplete follow-up. Future comparisons could be focused on the pattern of drug resistance in biologically defined subgroups; relevant acute and long-term toxicities; quality of life issues; relationship between long-term sequelae and dosages of certain chemotherapeutic agents (eg anthracyclines, epipodophyllotoxins, alkylating agents and glucocorticoids); and efficacy and toxicities of subclinical CNS treatment.
Regarding the comparison of toxicity data, J Shuster cautioned that the criteria of reported toxicities have undergone dramatic changes in recent years and suggested that future meetings should discuss the common toxicity data to be collected. G Masera remarked that efforts should be made to distinguish the cause of the event (eg death before or after chemotherapy). M Relling acknowledged the difficulty but importance in collecting the data on therapy actually delivered to the patients. B Camitta noted that the rates of induction failure in the reported studies ranged from 1% to 4% (median, 1.9%), induction death from 0.4% to 2.2% (median, 0.9%), and death in remission from 1.1% to 2.7% (median, 1.7%), and second cancers varied widely in the frequency and type. Studies could be conducted to determine the causes of the adverse events. M Schrappe shared the data on toxic deaths in their BFM 95 trial. Among 2115 patients enrolled, 27 died during induction and 34 died in remission; sepsis and pneumonitis were the most common causes of death. OB Eden mentioned that their groups have examined the outcome of 48 patients who had induction failure due to resistant disease. None of 27 patients treated with chemotherapy as compared to 11 of 21 treated with transplantation were still in first complete remission. After much discussion, participants agreed to study cases with induction failure due to refractory leukemia, and therapy-related deaths in each treatment phase. It was decided that the analysis of development of second cancer is best conducted within each group, as it is not only affected by the host pharmacogenetics but by the treatment administered, which varies widely between the clinical trials.
Except for CNS and testicular relapse, little is known about other extramedullary relapses, as noted by G Masera. There was also enthusiasm to determine the frequency, prognostic factors, and clinical outcome of these rare events.
Risk classification in ALL
B Camitta presented the proposed new risk classification of the COG. B-lineage cases will be classified into four groups based on presenting clinical and biological features as well as Leukemia early treatment response (day 7 or day 14 bone marrow result): low risk (ෂ35%), standard risk (ෂ45%), high risk (ෂ15%) and very high risk (ෂ5%). Very high-risk cases are those with Ph chromosome or BCR-ABL fusion, hypodiploidy Ͻ45, DNA index Ͻ0.81 or initial induction failure. In their recent analyses, the presence of trisomies 4, 10 and 17 was associated with very favorable prognosis. 7, 13 Hence, low-risk cases included those who are 1 to 9 years old with leukocyte count Ͻ50 × 10 9 /l (standard risk by Rome/NCI criteria), have either trisomies 4, 10 and 17 or TEL-AML1 fusion, and have rapid early response; they must not have E2A-PBX1 fusion, BCR-ABL fusion, MLL rearrangement, CNS leukemia or testicular involvement. Rome/NCI standard-risk cases without trisomies 4, 10 and 17 or TEL-AML1 fusion and those with one of these genetic features but slow early response will be classified as standard risk. The remaining cases will be considered high risk. However, whether TEL-AML1 fusion will be included as a favorable feature in the final classification is still under discussion.
Several recent studies indicated that measurement of minimal residual leukemia (MRD) could further improve risk assessment.
36-38 A Biondi described the strategy for BerlinFrankfurt-Mü nster (BFM) and Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) groups in using realtime quantitative polymerase chain reaction (PCR), applying TaqMan technology in quantitative assessment of MRD. 39, 40 They have identified germ-line probes that allow the detection of the most frequently occurring immunoglobulin and T cell receptor gene recombinations. To date, of the 377 cases evaluated prospectively, 75% to 80% were successful studies by this methods. He also showed the potential of light Cycler real-time PCR technology to quantify MRD. 41 This is a sensitive, specific and rapid method that needs no post-PCR handling, hence reducing the risk of contamination and saving time. M Schrappe indicated that in the BFM-AIEOP 2000 study, MRD assessment is being used for risk stratification. Cases with no detectable MRD at 5 weeks and 12 weeks from diagnosis are classified as standard-risk, and those with high levels of MRD (Ͼ10 −3 ) detectable at both time points, together with patients who have the Ph chromosome, the t(4;11) or initial induction failure, are considered as high-risk. All the others are considered to have medium-risk leukemia. In their recently completed study, the event-free survival was 98% ± 2% in the 55 standard-risk cases as defined by the MRD results, 80% ± 6% in the 50 with medium-risk leukemia, and 21% ± 8% in the 24 with high-risk disease.
D Campana introduced flow cytometric detection of aberrant immunophenotypes as another promising method to measure the MRD. Using four-color flow cytometer, 80% of B-lineage cases and virtually all T cell cases can be studied by this method. In fact, flow cytometry data can be electronically transferred from one center to the other for analyses. More recently, comparative analysis of gene expression in normal B cell progenitors and B-lineage leukemic cells identified new leukemia-associated markers (eg CD58), 42 boosting the cases that can be studied by flow cytometry to 90%. Tandem application of flow cytometry and PCR testing resulted in the successful study of 100% of the ALL cases. 43 a result which has now been extended to 97 consecutive cases. MRD levels at the end of induction and at week 14 of continuation therapy have independent predictive strength, after adjusting for other prognostic factors, including the day 8 peripheral blood response. 44 Interestingly, 50% of the patients had negative MRD after 2 weeks of remission induction therapy, 45 and they had a particularly favorable prognosis. Current SJCRH Total Therapy Study XV has incorporated MRD results into the risk classification scheme. 46 Patients with MRD level у1% at the end of 6-week remission induction and those with MRD level у0.1% at week 14 post-remission, are candidates for allogeneic hematopoietic stem cell transplantation. Another interesting observation is that the MRD levels in peripheral blood and bone marrow are virtually linearly correlated in T-lineage, but not in B-lineage ALL cases. In B-lineage cases, there is a group of patients who have detectable MRD in bone marrow but not in peripheral blood. Further studies are needed to determine the clinical and biological relevance of this finding.
H Riehm presented a simple risk classification based on morphologic examination of day 8 peripheral blood and day 15 bone marrow. In the BFM 90 and 95 studies, the 460 patients who have cleared circulating blasts on day 8 and have an M1 bone marrow on day 15 have an event-free survival of 90% ± 2%; the 1363 patients with one to 999 blasts/mm 3 of blood on day 8 plus M1 or M2 bone marrow on day 15, or with у1000 blasts/mm 3 of blood on day 8 plus M1 bone marrow on day 15, have an event-free survival of 81% ± 1%; and the 444 patients with у1000 blasts/mm 3 of blood on day 8 plus M3 bone marrow on day 15, induction failure, Ph chromosome or the t(4;11), have an event-free survival of 46% ± 3%. The advantage of this classification system is that it can be easily adopted by centers without the capability of measuring MRD.
Glucocorticoid treatment and its pharmacogenetics
P Gaynon reviewed the background information of glucocorticoid treatment. In the Children's Cancer Group (CCG)-1891 study, double-delayed intensification (including dexamethasone) improved treatment outcome (compared to a single course of delayed intensification) for intermediate-risk cases. 7 In the CCG-1922 study of Rome/NCI standard-risk ALL, patients randomized to receive dexamethasone during induction and continuation phases have significantly better treatment outcome than those treated with prednisone. 7 Dexamethasone was associated with a higher frequency of myopathy, hyperglycemia and hypogammaglobulinemia than prednisone. In contrast to the experience of Dana-Farber Cancer Institute (DFCI) pilot protocol 91-01P 47 and that of the POG 9906 and 9407 studies in which dexamethasone resulted in excessive toxicities during remission induction, dexamethasone was well tolerated in the CCG-1922 trial 7 and Dutch Childhood Leukemia Study Group (DCLSG) ALL 6 protocol. 48 Perhaps, other concomitant treatment contributed to the difference in toxicities.
One of the major concerns of intensive dexamethasone treatment is the development of avascular necrosis of bone, which predominantly affects older children (у10 years of age). 49 Preliminary results of the CCG studies indicated that intermittent use of dexamethasone would reduce the risk of this complication. A Veerman reviewed the frequency of this complication in three consecutive DCLSG protocols. Interestingly, none of the 166 patients treated in the DCLSG ALL 6 protocol featuring high-dose dexamethasone developed this complication. By contrast, of the other 374 patients treated in ALL 7 and ALL 8 protocols, which contained low-dose dexamethasone but multiple other agents including prednisone, nine (eight of whom were 12 years of age or older) developed avascular necrosis of bone. He suggested that multi-agent treatment rather than dexamethasone alone induced this complication. L Silverman commented that in the DFCI studies, compared to prednisone, dexamethasone treatment resulted in more bone fractures but not more avascular necrosis of bone.
M Schrappe reported that in the BFM 2000 study, patients were randomized to receive prednisone or dexamethasone during remission induction. Early results suggested that the time to attain complete remission was identical in the two arms and patients treated with dexamethasone at 10 mg/m 2 per day were more moody and depressed, had more gastrointestinal and hepatic toxicities, and perhaps were more neutropenic. In the BFM 90 study, day 8 prednisone response was a powerful prognostic indicator, within all subgroups as defined by age, leukocyte count, immunophenotypes and Rome/NCI risk criteria. 50 Glutathione S-transferase (GSTT1) may be associated with prednisone response. H Riehm emphasized that upfront prednisone treatment would not compromise ultimate treatment outcome.
M Relling discussed three issues related to glucocorticoids: their capacity to induce gene expression, replacement of oral prednisone with intravenous methylprednisolone, and pharmacogenetics of steroids in ALL. Glucocorticoids induce the expression of numerous genes, many involved in resistance to and metabolism of anticancer drugs. They induce CYP3A4, for example, so that etoposide clearance is over two-fold higher after prednisone treatment. Data comparing antiinflammatory, immunosuppressive, cortisol-suppressive and anti-leukemic effects of prednisone, methylprednisolone and dexamethasone 51, 52 were discussed. Methylprednisolone may be more potent than previously appreciated and SJCRH investigators have now converted its dosage to 50% (instead of 80%) of that of prednisone. Methylprednisolone use was more common during remission induction in St Jude Total Therapy Study XIV, a prototcol in which three early deaths occurred among only 53 patients, resulting in early closure of the study. However, methylprednisolone use could not be clearly linked to toxicity on the study, and careful investigation failed to identify a single factor contributing to the cause. A number of modifications were made in the current Total Therapy Study XV, in which remission induction has been well tolerated. Newly characterized polymorphisms in genes involved in the metabolism of glucocorticoids, CYP3A4 and CYP3A5, 53 were discussed. CYP3A4*1B frequencies in ALL and in therapyrelated acute myeloid leukemia were not different, after adjustment for race. Preliminary data were presented on genotype distributions among 53 patients with ALL for CYP3A4, CYP3A5, glucocorticoid receptor, UDP-glucuronosyl-transferase (UGT1A1) and vitamin D receptor polymorphisms, according to the presence or not of avascular necrosis of bone; analysis is ongoing.
R Pieters commented that additional polymorphisms of the glucocorticoid receptor gene on chromosome 5 may also affect steroid response.
Treatment of T cell and high-risk ALL
J Shuster presented interim analysis of the POG 9404 study for T cell ALL and stage III or IV lymphoblastic lymphoma. This randomized trial evaluates the efficacy of high-dose methotrexate (5 g/m 2 , given every 3 weeks for four doses) when added to the multi-agent chemotherapy backbone of the DFCI-87-01 study, and determines the role of the cardioprotectant (dexrazoxane) in preventing cardiotoxicity. The data showed that high-dose methotrexate significantly improved outcome for both T cell ALL and lymphoblastic lymphoma, with an encouraging 3-year event-free survival of 85% ± 7% and 87% ± 10%, respectively. The impact was particularly striking in T cell ALL cases with leukocyte count у50 × 10 9 /l. Because of this significant finding, all subsequent patients will receive high-dose methotrexate, but the randomization for dexrazoxane treatment will continue. J Shuster raised the issue of the role of cranial irradiation for subclinical CNS therapy in T cell ALL. To test this question with confidence would require international collaboration because 1440 patients are needed. J Nachman mentioned that in a CCG study, T cell ALL cases with good early response fared well without cranial irradiation. OB Eden mentioned that in the UKALL XI trial, children receiving cranial irradiation exhibited poorer neuropsychological performance compared to those receiving highdose methotrexate, in terms of distractibility and processing speed indices as well as spelling and numeracy. 54 There was no significant difference in the IQ or academic attainments between patients treated with 16 doses of intrathecal methotrexate over 2 years and those who received the same intrathecal therapy plus three doses of high-dose methotrexate. M Schrappe commented that in the BFM studies, 12 Gy cranial irradiation was as effective as 18 Gy, 50 and that neurotoxicity was less with four doses of high-dose methotrexate than with cranial irradiation. He further remarked that in an AIEOP study, increased systemic relapse was observed in T cell ALL cases with leukocyte count у100 × 10 9 /l when cranial irradiation was not given, although the asparaginase formulation may not have been optimal in this study. 55 Clearly, more studies are needed on this issue, given the heterogeneity of T cell ALL.
M Schrappe presented the indications for matched-related allogeneic transplantation in the BFM study, including T cell ALL, pro-B (CD10 − ) ALL or BFM risk factor у1.7 (ෂleukocyte count Ͼ100 × 10 9 /l) with poor prednisone response; the presence of Ph chromosome or t(4;11); and failure to achieve a complete remission at day 33. Ph + ALL cases with poor prednisone response are also candidates for matched-unrelated transplant.
R Handgretinger presented data on transplant with haploidentical donors in patients lacking other suitable donors. The procedure involves magnetic-activated cell sorting of CD34 + cells and yields a purity to 98.2% with very low contamination of T cells or B cells. Graft-versus-host (GVH) prophylaxis is not necessary with this type of transplant. Of 48 patients treated, 47 engrafted with no grade 3 or 4 acute or chronic GVH disease. Major causes of failure were relapse and viral infection. There were no cases with EBV-associated lymphoproliferative syndrome. Of the 15 refractory ALL cases treated, the event-free survival was 45% ± 15%. Low naturalkiller cell activity was associated with a high risk of failure (all 10 cases failed as compared to five of 15 with high activity). Natural killer activity could be augmented in vivo with interleukin-2 treatment. This promising procedure will be pursued further at SJCRH because of the relatively large number of ethnic minority patients who often lack matched unrelated donors.
Investigational agents
The development of new agents to treat childhood ALL is critically linked to the current understanding of the molecular processes regulating leukemic cell survival and apoptosis induction. B Anderson reviewed the new 'molecularly targeted' agents primarily aimed at aberrant intracellular processes that Leukemia allow malignant cells to produce survival proteins, avoid appropriate cell cycle regulatory mechanisms, or repair therapy-induced damage.
Tyrosine kinase inhibitor (STI-571)
The BCR-ABL fusion gene of Ph + leukemias results in p210 BCR-ABL and p190 BCR-ABL tyrosine kinase products, whose activity provides survival and proliferative signals required for ongoing replication of the leukemic clone. 56 STI-571 selectively inhibits the BCR-ABL tyrosine kinase, leading to growth inhibition and apoptosis of BCR-ABL positive cells. 57 Phase I and II clinical trials in adults with chronic myeloid leukemia have shown the compound to be generally well tolerated, with no dose-limiting toxicities. There have been 100% hematologic responses and 35% complete and major cytogenetic responses in patients treated with doses of 300 mg or greater. 58 A pediatric phase I trial of STI-571 in children with relapsed Ph + ALL is currently underway and a pilot study of STI-571 administration in combination with standard chemotherapy will soon be initiated in newly diagnosed children with Ph + ALL.
Proteasome inhibitor (PS-341)
The ubiquitin-proteasome pathway is a principal pathway for intracellular protein degradation, 59 resulting in the ordered and temporal degradation of cyclin, cyclin-dependent kinases and tumor suppressor proteins necessary for cell cycle progression and mitosis. Additionally, NF-B, a transcription factor causing production of apoptosis inhibitors, is indirectly activated by the proteasome. Constitutively activated NF-B complexes have been found in a majority (39 out of 42 samples) of childhood ALL, without any subtype restriction, 60 suggesting that NF-B may play an important role in leukemic cell survival. Proteasome inhibitors down-regulate NF-B and stabilize p53 and other cell-cycle regulatory proteins, leading to apoptosis in cells that are continuously dividing. 61 An assay is available using peripheral blood cells that enables investigators to easily monitor the degree of proteasome inhibition achieved. 62 PS-341 is a proteasome inhibitor 63, 64 that has been evaluated in adult studies using several intravenous-dosing schedules with minimal toxicity noted at doses evaluated to date. 65, 66 Activity has been detected in multiple myeloma and an adult leukemia trial is ongoing. Phase I testing in children with solid tumors has been initiated recently.
Cell cycle checkpoint inhibitor (UCN-01)
Chemotherapy-induced DNA damage may be repaired in malignant cells following cell cycle checkpoint arrest, which can allow time for repair of DNA damage prior to either DNA synthesis or mitosis. Agents are now being developed that target proteins involved in cell cycle arrest. 67 UCN-01 (7-hydroxy-staurosporine) inhibits cyclin-dependent kinase activity, important in transition checkpoint regulation, and demonstrates antiproliferative activity in several human tumor cell lines. UCN-01 also inhibits kinases involved in cell cycle arrest in response to DNA damage. In the presence of UCN-01, damaged cells proceed toward mitosis and subsequent apoptosis, rather than checkpoint arrest and DNA repair. UCN-01 abrogates cisplatin-induced G2 arrest and campto-Leukemia thecin (CPT)-induced S-and G2-phase checkpoints, enhancing the cytotoxicity induced by cisplatin and CPT. 68, 69 Childhood T cell ALL cells lacking p16 expression, a cyclindependent kinase inhibitor, have been found to be differentially sensitive to UCN-01, suggesting that p16 protein expression status may influence the toxicity of UCN-01 in T cell ALL 70 and that UCN-01 may be active in p16 negative T cell ALL. Phase I studies in adults have revealed an extremely long half-life (253 to 1660 h) for UCN-01, because of the high affinity binding to alpha 1-acid glycoprotein. 71 Clinical studies of the agent combined with cytarabine are underway in adults with chronic lymphocytic leukemia and non-Hodgkin's lymphoma, in the hope that UCN-01 may enhance the activity of cytarabine as demonstrated in vitro. 72 
Genasense
The BCL-2 gene is overexpressed in a variety of cancers and promotes cell survival by blocking spontaneous apoptosis. 73 BCL-2 expression can result in the inherent and acquired resistance of malignant cells to chemotherapy, radiotherapy and immunotherapy. Genasense (Genta Inc, USA; code G3139), an 18 mer phosphorothioate oligonucleotide designed to bind to the first six codons of the human BCL-2 mRNA, reduces BCL-2 protein levels in vitro. 74 BCL-2 antisense oligonucleotides have been shown to enhance the sensitivity of ALL and lymphoma cells to conventional cytotoxic agents, such as cytarabine and methotrexate. 75, 76 Early trials in patients with malignant melanoma and lymphoma have demonstrated down-regulation of BCL-2 expression in target tissues and also in peripheral blood lymphocytes. Combination studies in adult leukemia have been performed in which 10 days of continuous Genasense infusion is combined with FLAG therapy (Fludarabine, Ara-C, G-CSF) starting on day 5. BCL-2 expression has been shown to decrease to biologically significant levels with 3-4 days of Genasense infusion. Conflicting reports exist regarding the clinical relevance of BCL-2 expression in childhood ALL [77] [78] [79] and the influence of BCL-2 expression on in vitro leukemic cell sensitivity. 80 Clinical trials of Genasense in combination with standard chemotherapy will be necessary to demonstrate whether a decrease in BCL-2 expression influences the effectiveness of the chemotherapeutic regimen in childhood ALL.
Campath-1H
Campath-1H is a humanized monoclonal antibody targeting the CD52 antigen which is found on the majority of lymphocytes, monocytes and macrophages 81 and has also been identified on childhood ALL cells. While lymphocytes are lysed by Campath-1H in the presence of complement, 82 the antibody can also induce human chronic lymphocytic leukemia cells to undergo apoptosis in vitro independent of complement mediated lysis. 83 This antibody has undergone extensive testing, and demonstrated significant activity in adult chronic lymphocytic leukemia, non-Hodgkin's lymphoma and ALL. [84] [85] [86] [87] [88] A murine form of Campath-1 has been used in pediatric bone marrow transplant for purposes of controlling GVH disease. 89 Supportive care measures are required with the use of Campath-1H due to the prolonged immunosuppression induced by the antibody clearance of immune effector cells and the initial immunologic reaction to the antibody infusion. Plans are currently under development to evaluate Campath-1H as a single agent and in combination with standard induction agents for children with second ALL relapse.
